PURPOSE: The purpose of this article was to assess the impact of intravenous (IV) anticholinergic hyoscine butylbromide in abdominal magnetic resonance (MR) imaging with oral magnetic particles (OMP) [ABDOS-CAN, Ferristene (USAN), Nycomed Imaging AS, Oslo, Norway]. MATERIALS AND METHODS: In 31 patients with abdominal tumors, T1-weighted spin-echo (SE) images (SE 600/ 15; 1.5 T) were obtained without and with IV hyoscine butylbromide (20 mg) before and after administration of 800 ml of OMP. Two blinded readers assessed motion artifacts, bowel-wall visualization, and lesion delineation on the four sets of T1-weighted images. The two-tailed Wilcoxon paired sample test was used for statistical analysis (p < .05). RESULTS: Hyoscine butylbromide reduced motion artifacts and improved bowel-wall visualization on precontrast and OMP-enhanced images at a statistically significant level (p = 0.0006-0.037). The lowest degree of artifacts was recorded on OMP images with hyoscine butylbromide. OMP with hyoscine butylbromide significantly improved lesion delineation compared to studies without antiperistaltic drug before (p = 0.019) and after OMP administration (p = 0.01). CONCLUSIONS: The authors conclude that the use of IV hyoscine butylbromide is recommended for OMP-enhanced abdominal MR imaging with T1-weighted SE pulse sequences at 1.5 T.
PURPOSE: The purpose of this article was to assess the impact of intravenous (IV) anticholinergic hyoscine butylbromide in abdominal magnetic resonance (MR) imaging with oral magnetic particles (OMP) [ABDOS-CAN, Ferristene (USAN), Nycomed Imaging AS, Oslo, Norway]. MATERIALS AND METHODS: In 31 patients with abdominal tumors, T1-weighted spin-echo (SE) images (SE 600/ 15; 1.5 T) were obtained without and with IV hyoscine butylbromide (20 mg) before and after administration of 800 ml of OMP. Two blinded readers assessed motion artifacts, bowel-wall visualization, and lesion delineation on the four sets of T1-weighted images. The two-tailed Wilcoxon paired sample test was used for statistical analysis (p < .05). RESULTS:Hyoscine butylbromide reduced motion artifacts and improved bowel-wall visualization on precontrast and OMP-enhanced images at a statistically significant level (p = 0.0006-0.037). The lowest degree of artifacts was recorded on OMP images with hyoscine butylbromide. OMP with hyoscine butylbromide significantly improved lesion delineation compared to studies without antiperistaltic drug before (p = 0.019) and after OMP administration (p = 0.01). CONCLUSIONS: The authors conclude that the use of IV hyoscine butylbromide is recommended for OMP-enhanced abdominal MR imaging with T1-weighted SE pulse sequences at 1.5 T.
Authors: Andreas Gutzeit; Christoph A Binkert; Dow-Mu Koh; Klaus Hergan; Constantin von Weymarn; Nicole Graf; Michael A Patak; Justus E Roos; Marcus Horstmann; Sebastian Kos; Simone Hungerbühler; Johannes M Froehlich Journal: Eur Radiol Date: 2012-01-22 Impact factor: 5.315
Authors: Johannes M Froehlich; Muriel Daenzer; Constantin von Weymarn; S Mehmet Erturk; Christoph L Zollikofer; Michael A Patak Journal: Eur Radiol Date: 2009-02-04 Impact factor: 5.315
Authors: Cynthia Schmidt; Andreas M Hötker; Urs J Muehlematter; Irene A Burger; Olivio F Donati; Borna K Barth Journal: Abdom Radiol (NY) Date: 2021-03-26
Authors: Finbar Slevin; Matthew Beasley; Jim Zhong; Eleanor Hudson; Richard Speight; John Lilley; Louise J Murray; Ann M Henry Journal: BJR Open Date: 2021-07-29